The 3rd International Rare Diseases Research Consortium (IRDiRC) Conference, will be held on February 8-9, 2016, in Paris, France. The conference gathers stakeholders from around the world to share their experience, knowledge and points of view to shape and advance rare diseases research through foundational, diagnostics, therapeutics and policy development. The full listing of speakers is available online on the IRDiRC Conference website.
Confirmed speakers for the 3rd IRDiRC Conference include:
- Christopher Austin, National Center for Advancing Translational Sciences (NCATS), USA
- Claudio Bordignon, MolMed S.p.A., Italy
- Kym Boycott, Children’s Hospital Eastern Ontario, Canada
- Ruxandra Draghia-Akli, European Commission – DG Research and Innovation (DG RTD), Belgium
- Jonathan Goldsmith, US Food and Drug Administration (FDA), USA
- Melissa Haendel, Monarch Initiative and Oregon Health & Science University, USA
- Edmund Jessop, National Health Service (NHS) England, UK
- Sangeeta Jethwa, Roche Innovation Centre, Switzerland
- Matt Might, University of Utah, USA
- Sophie Nicole, Université Pierre et Marie Curie, France
- Anders Olauson, Ågrenska Foundation, Sweden
- Slavé Petrovski, University of Melbourne, Australia
- Kiran Reddy, Clarus Ventures LLC, USA
- Makoto Suematsu, Japan Agency for Medical Research and Development (AMED), Japan
- Toshiki Takenouchi, Keio University, Japan
- Sonia Vallabh & Eric Minikel, Broad Institute, USA
- Nan Wu, Peking Union Medical College Hospital, China
The strong and exciting program, now online, consists of 4 plenary and 3 parallel sessions. The conference kicks off with an overview of the history and achievements of IRDiRC five year after it was launched. This will be followed by a global view of rare diseases research in 2017, and the state of foundational, diagnostics and therapeutics research.
The first parallel session elaborates further the state of research today, with interesting talks on topics including data standards and exchange, undiagnosed diseases and ex-vivo stem cell therapy. The second parallel session focuses on new approaches to rare diseases and highlights the work of innovative young investigators. The third parallel session provides an overview of trends in the fields of patient advocacy, companies, and regulatory and access.
The conference closes with a forward look plenary to discuss ways to transform rare diseases research over the course of the next 10 years, including a panel discussion on the next set of IRDiRC goals for 2017-2027. Participation and input of the community are vital so we can work together to bring diagnoses and therapies to all rare diseases patients.
Register now and join us in carving out the future of rare diseases research. Abstract submission and early registration deadline is extended to December 7, 2016.
We look forward to welcoming you in Paris, France, in February 2017!